Epigenetic and Posttranscriptional Modulation of SOS1 Can Promote Breast Cancer Metastasis through Obesity-Activated c-Met Signaling in African-American Women.
Black or African American
/ statistics & numerical data
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ pharmacology
Apoptosis
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ drug therapy
Cell Proliferation
Epigenesis, Genetic
Female
GRB2 Adaptor Protein
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ drug therapy
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Nude
Obesity
/ physiopathology
Prognosis
Proto-Oncogene Proteins c-met
/ genetics
Quercetin
/ analogs & derivatives
SOS1 Protein
/ genetics
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
27
12
2019
revised:
28
07
2020
accepted:
07
01
2021
pubmed:
16
1
2021
medline:
5
11
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
Ethnicity is considered to be one of the major risk factors in certain subtypes of breast cancer. However, the mechanism of this racial disparity remains poorly understood. Here, we demonstrate that SOS1, a key regulator of Ras pathway, is highly expressed in African-American (AA) patients with breast cancer compared with Caucasian-American patients. Because of the higher obesity rate in AA women, increased levels of SOS1 facilitated signal transduction of the c-Met pathway, which was highly activated in AA patients with breast cancer via hepatocyte growth factor secreted from adipocytes. Elevated expression of SOS1 also enhanced cancer stemness through upregulation of PTTG1 and promoted M2 polarization of macrophages by CCL2 in metastatic sites. SOS1 was epigenetically regulated by a super-enhancer identified by H3K27ac in AA patients. Knockout of the super-enhancer by CRISPR in AA cell lines significantly reduced SOS1 expression. Furthermore, SOS1 was posttranscriptionally regulated by miR-483 whose expression is reduced in AA patients through histone trimethylation (H3K27me3) on its promoter. The natural compound, taxifolin, suppressed signaling transduction of SOS1 by blocking the interaction between SOS1 and Grb2, suggesting a potential utility of this compound as a therapeutic agent for AA patients with breast cancer. SIGNIFICANCE: These findings elucidate the signaling network of SOS1-mediated metastasis in African-American patients, from the epigenetic upregulation of SOS1 to the identification of taxifolin as a potential therapeutic strategy against SOS1-driven tumor progression.
Identifiants
pubmed: 33446575
pii: 0008-5472.CAN-19-4031
doi: 10.1158/0008-5472.CAN-19-4031
pmc: PMC8178187
mid: NIHMS1665271
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Biomarkers, Tumor
0
GRB2 Adaptor Protein
0
GRB2 protein, human
0
SOS1 Protein
0
SOS1 protein, human
0
Quercetin
9IKM0I5T1E
taxifolin
9SOB9E3987
MET protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3008-3021Subventions
Organisme : NCI NIH HHS
ID : R37 CA230451
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205067
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA185650
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA173499
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA247819
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
pubmed: 22128289
J Health Care Poor Underserved. 2014 Feb;25(1):257-75
pubmed: 24509025
Breast Cancer Res. 2018 Sep 4;20(1):104
pubmed: 30180888
Cancers (Basel). 2018 Dec 14;10(12):
pubmed: 30558195
Eur J Hum Genet. 2015 Nov;23(11):1531-7
pubmed: 25712082
Mol Syst Biol. 2010 Jun 8;6:377
pubmed: 20531406
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):16-28
pubmed: 28108348
Oncotarget. 2015 May 10;6(13):11231-41
pubmed: 25868978
Inflammation. 2017 Jun;40(3):1072-1086
pubmed: 28365872
Nat Rev Cancer. 2003 Jan;3(1):11-22
pubmed: 12509763
J Biol Chem. 2012 Jun 1;287(23):19516-27
pubmed: 22511756
Carcinogenesis. 2017 Aug 1;38(8):757-765
pubmed: 28430867
Neoplasia. 2018 Mar;20(3):289-294
pubmed: 29471289
Genes Dev. 2013 Dec 1;27(23):2543-8
pubmed: 24298054
Int J Environ Res Public Health. 2017 May 05;14(5):
pubmed: 28475137
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2006 Dec 15;66(24):11983-90
pubmed: 17178897
PLoS One. 2012;7(5):e37928
pubmed: 22701537
Oncol Rep. 2019 Dec;42(6):2537-2549
pubmed: 31638193
Genes Cancer. 2011 Mar;2(3):359-72
pubmed: 21779505
Pflugers Arch. 2017 Apr;469(3-4):385-396
pubmed: 28233125
Oncogene. 2004 Jul 22;23(33):5675-81
pubmed: 15184886
Cancer Res. 2016 Sep 1;76(17):4970-80
pubmed: 27364556
J Recept Signal Transduct Res. 2013 Apr;33(2):124-8
pubmed: 23528009
Obes Res. 2004 Oct;12(10):1680-9
pubmed: 15536232
Epigenetics. 2015;10(12):1177-87
pubmed: 26680018
Oncotarget. 2016 Nov 29;7(48):79274-79291
pubmed: 27813494
PLoS One. 2013 Nov 18;8(11):e71915
pubmed: 24260093
Cancer Prev Res (Phila). 2012 Sep;5(9):1103-14
pubmed: 22805054
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
pubmed: 28472234
Genes Chromosomes Cancer. 2008 Mar;47(3):253-9
pubmed: 18064648
Sci Transl Med. 2018 Mar 14;10(432):
pubmed: 29540614
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
J Innate Immun. 2015;7(6):647-58
pubmed: 26138727
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Breast Cancer Res. 2018 Jun 5;20(1):45
pubmed: 29871690
PLoS One. 2010 Oct 29;5(10):e13735
pubmed: 21060830
J Biol Chem. 1994 Jun 3;269(22):15756-61
pubmed: 8195229
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560
pubmed: 30683722
Oncologist. 2012;17(3):312-20
pubmed: 22382457
J Clin Invest. 2007 Sep;117(9):2362-8
pubmed: 17786229
Genome Biol. 2012 Feb 09;13(2):R8
pubmed: 22322129
Nature. 2017 Jan 5;541(7635):81-86
pubmed: 28002404
Pharmacogenomics. 2014 Aug;15(11):1507-18
pubmed: 25303301
J Hematol Oncol. 2019 Sep 10;12(1):95
pubmed: 31500658
PLoS One. 2016 Apr 25;11(4):e0153125
pubmed: 27111221
Clin Cancer Res. 2004 Mar 15;10(6):2052-7
pubmed: 15041725
Oncotarget. 2015 Jun 30;6(18):16507-16
pubmed: 25980493
Respir Res. 2016 Mar 08;17:24
pubmed: 26956558
J Cell Commun Signal. 2018 Mar;12(1):119-132
pubmed: 29188479
Front Biosci (Landmark Ed). 2017 Jan 1;22(5):772-782
pubmed: 27814645
Int J Surg. 2016 Apr;28:179-84
pubmed: 26957017
Mol Pharm. 2017 May 1;14(5):1548-1557
pubmed: 28060514
Hum Mutat. 2011 Jul;32(7):760-72
pubmed: 21387466
Cold Spring Harb Perspect Biol. 2016 Apr 01;8(4):a019521
pubmed: 27037415
Mol Cell Biol. 1996 Oct;16(10):5674-82
pubmed: 8816480
FASEB J. 1999 Jan;13(1):31-8
pubmed: 9872927
Carcinogenesis. 2019 Mar 12;40(1):61-69
pubmed: 30321299
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261771
Int J Oncol. 2009 Oct;35(4):751-60
pubmed: 19724911
Clin Epigenetics. 2016 Feb 16;8:17
pubmed: 26884818
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2913-23
pubmed: 18990731
Breast Cancer Res. 2013 Jun 27;15(3):208
pubmed: 23826992
Cancer. 2012 Mar 1;118(5):1334-44
pubmed: 21800289